Safety Data

AE=adverse event; BID=twice daily; csDMARD=conventional synthetic disease-modifying antirheumatic drug; DMARD=disease-modifying antirheumatic drug; GI=gastrointestinal; JAK=Janus kinase; JAKi=Janus kinase inhibitor; LTE=long-term extension; MOA=mechanism of action; NMSC=nonmelanoma skin cancer; PsA=psoriatic arthritis; pt-yr=patient-year; RA=rheumatoid arthritis; TADD=total average daily dose.
References: 1. XELJANZ/XELJANZ XR [prescribing information]. New York, NY: Pfizer Inc.; December 2019. 2. Data on file. Pfizer Inc., New York, NY.